TITLE: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)

SPONSOR: AstraZeneca AB

Primary InvestigatorKristle Lynch, MD

CONTACT: Maureen DeMarshall, BSN, RN (demarshm@pennmedicine.upenn.edu or 215-349-8546)

  • A Phase 3 study to investigate the use of tezepelumab as a treatment for patients with EoE.  
  • 52 weeks 1:1:1 (210mg Q4wks, 420mg Q4 weeks, or placebo) followed by 24 weeks OLE (210mg vs 420mg Q4 weeks)

And

TITLE: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The “EvolvE” Study)

SPONSOR: Celldex Therapeutics

Primary Investigator: Gary W. Falk, MD

CONTACT: Maureen DeMarshall, BSN, RN (demarshm@pennmedicine.upenn.edu or 215-349-8546)

  • A Phase 2 study of barzolvolimab, a monoclonal antibody  
  • 16 weeks 1:1 (300mg q8weeks vs. Placebo) followed by 12 weeks OLE

 

Share This Page: